肝素的终端PEGylation:对抗凝血剂活性的影响和与原胺的复杂化
Sandra Amaral1, Tamara Lozano-Fernández2, Juan Sabin3
13B's Research Group, I3B's Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, 4805-017 Barco, Portugal; ICVS/3B's - PT Government Associate Laboratory, University of Minho, Portugal.
这项研究开发了一种新型的氨酸-聚乙烯甘醇合物 (Hep-b-PEG),它保持抗凝活性,延长半衰期,并与质氨酸形成稳定的复合物,克服了当前抗凝剂的局限性.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 材料科学 材料科学 材料科学
背景情况:
- 氨酸是一种广泛使用的抗凝剂,其限制包括短半衰期和次要作用.
- 低分子量肝素类似物缺乏蛋白胺中和性,限制了临床应用.
- 现有的抗凝剂在有效性和安全性方面存在挑战.
研究的目的:
- 开发一种改性肝素,其药理动力学和安全性状况得到改善.
- 将聚乙烯甘醇 (PEG) 通过氧基结与肝素结合,形成Hep-b-PEG.
- 为了评估Hep-b-PEG与抗素III (AT) 和蛋白质胺的相互作用.
主要方法:
- 异热定位热度计 (ITC) 用于评估与AT的结合亲和力.
- 动态光散射 (DLS) 用于分析复杂的形成与protamine.
- 在体外 (人体血) 和体内 (老鼠) 研究以评估抗凝剂活性和半衰期.
主要成果:
- 乙肝-b-PEG对抗血素III (AT) 具有持续的亲和力.
- 乙-PEG与原胺形成了稳定的纳米复合物,避免了有问题的聚合物.
- 结合物在体外和体外模型中表现出延长半衰期和增强的抗凝剂活性.
结论:
- 乙PEG是一种有前途的抗凝剂,稳定性和安全性得到改善.
- 开发的结合剂克服了传统肝素疗法的关键局限性.
- 这种修改为抗凝固剂治疗策略提供了潜在的进步.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Venous Thrombosis III: Interprofessional Care
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...


